Animal study · Supplements / medicine · 20 Nov 2026
In mice, imeglimin lined up with less islet injury after transplant; human islets have not been tested
Source: Kyoto University
What the research found
A 20 November 2026 research note from Kyoto University, written in Japanese, reports mouse work by Muhammad Fauzi, Takaaki Murakami, Daisuke Yabe, and colleagues. Imeglimin, a medicine already used for type 2 diabetes, limited low-oxygen injury in mouse islets and lined up with better early engraftment and glucose control after islet transplant in a mouse model of type 1 diabetes. In the islet experiments, mitochondrial function held up and reactive oxygen species rose less. A receptor-targeted scan, indium-111 exendin-4 SPECT/CT, showed more beta-cell signal at day 14. The group says that scan is a tool they hope to use in care, and the figure in the release is a diagram, not a measured image. The paper appeared online in Diabetes on 18 November 2026 and was picked as a Paper of the Month. The authors say the next check has to be human islets. This is not a study of imeglimin for a longer life, and it is not a reason to start, stop, or swap a prescribed diabetes medicine. DOI 10.2337/db26-0360. Not medical advice.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
More supplements / medicine news
- In two phase 3 trials, retatrutide lined up with large weight loss and less knee pain, and joint damage was not shown to stop
- In mice, an experimental compound raised energy use and spared lean mass; human tests are still ahead
- In 720 patients with facial palsy, vitamin B12, vitamin D, protein intake, and a low index lined up with incomplete recovery
- Across 16 studies and 5,679 older adults, a higher medication burden lined up with higher odds of sarcopenia
- Across 64 Middle East and North Africa trials, intermediate vitamin D doses raised 25(OH)D, and higher doses added less